Alex Tikhonov

Had an amazing time at #SITC2024! The cutting-edge science was incredible, and the @sitcancerECS activities we organized were a blast. Loved connecting with colleagues and moderating the Rapid Oral Abstract Basics session. Thank you all for making it an awesome experience! 🙌

🚀 Exciting news! With @tatyanabobrrrr & @mab__b, we're starting the next round of "Janeway’s Immunology Journal Club!" 📚🌍 Last year, 5 months of meetings with 30 global participants! 🌟 Apply: forms.gle/anyvJDCnzAkaCd… #Immunology #JournalClub #Janeway

Please take a moment to listen to this; it's only 3 minutes long! podcasters.spotify.com/pod/show/ifcc/… @_EFLM @IFClinChem @myADLM @GMedLabWeek #globalmedlabweek

Join me and 3 excellent speakers, including @earlgrey_addict, today and learn how omics technologies can transform laboratory medicine in the next @IFClinChem webinar. Register for free here: workcast.com/register?cpak=…. @_EFLM @myADLM #clinicalchemistry #laboratormedicine #omics

A new method called Slide-tags lets scientists capture both genetic and location information of individual cells using standard single-cell workflows in the lab. The technology builds upon Slide-seq, both developed by the labs of @insitubiology & @macosko. broad.io/slide-tags

🔥🚨Hot off the press now in @TheLancetOncol, led by @waraonc23 with an excellent team @AminNassarMD @adib_elio @ZainAsadEP #Nobu and #Susu. Thank you @TheLancetOncol teams for the editorial support. @StephensonCC @SarahCannonDocs . Also read commentary !! thelancet.com/journals/lanon…

Very proud of this joint effort with Miki de Palma and colleagues - what a ride. We learned so much in this collaboration. Check out our latest paper in Nature Cancer - a novel way to treat several cancers - also liver cancer! More to come! nature.com/articles/s4301…

In a major milestone for science, for medicine, and for patients, the world’s first CRISPR drug has been approved in the UK. “A new treatment for sickle-cell disease and transfusion-dependent β-thalassemia has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for patients aged 12 and over after a rigorous assessment of its safety, quality and effectiveness.” Congratulations to the many scientists, doctors, patients, and industry leaders who made this development possible.🍻 gov.uk/government/new…

1/ We are excited to report in @Nature the discovery that human inborn errors of the alternative NF-κB pathway-dependent immunity underlie the development of auto-Abs neutralizing type I IFNs (rdcu.be/dqBBU).

1/Where do I start? Is it at Von Behring and Kitasato who were the first to discover that immunization of animals with diptheria and tetanus toxins resulted in soluble substances in the serum that neutralize these same toxins making them harmless? bit.ly/VonBehring1890

@Plasmacellguy Thanks, great thread!

Out today in @Nature, we describe HHV-6 reactivation in T cells, including therapeutic CAR T cells. I’m so grateful to have worked with an all-star team during my time in the @Satpathology lab that led to these findings. nature.com/articles/s4158… 1/n

@gulleyj1 @JennGuerriero Best picture!

Love this class of #Sparkies! #SITC23 ⁦@JennGuerriero⁩

Thanks James, you're an incredible mentor! Appreciate your support #SITC23 @sitcancer

#Sparkathon current and alumni Members at the @sitcancerECS reception in San Diego! @sitcancer annual meeting! #nextgeneration

Thrilled to be at #SITC2023 and a #Sparkathon Class 2023 Participant! Learning from the best in cancer immunotherapy and looking for new career opportunities. Message me if you are here and let’s connect! @sitcancerECS @sitcancer #cancerimmunotherapy

@BenWestphalen Will read all the insights!

A huge honor to be part of the illustrious and international group of superstars ✨ Looking forward to our virtual (and hopefully personal) engagements. Look out for news on #precisionmedicine & #pancsm 💜

Had an amazing time at the #2023FallCommitteeWeekend! Learned so much from colleagues and met awesome people. Proud to be part of the #DEISteeringCommittee and work towards a more inclusive and equitable society. #DiversityMatters #EquityForAll #InclusionIsPower @myADLM @opphd

In these horrific times in my homeland Israel its hard to celebrate a new study. But it's important to acknowledge the hard work of the team. A new machine learning tool by Markus Müller et al. for prioritization of neoantigens. #ack0010" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl…

Hot off the press in @NatureMedicine: Pleased to see stage 1 of our #ctDNA molecular response adaptive #clinicaltrial in print, supporting the value of ctDNA as an early endpoint of #immunotherapy response for patients with #lungcancer. 👉#OpenAccess link: rdcu.be/dn7Vj